News

Managed Healthcare Executive's most popular articles this year shed light on the biggest areas of interest to managed care organizations. Read more.

FDA recently approved rucaparib (Rubraca, Clovis Oncology) tablets to treat patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer, who have been treated with 2 or more chemotherapies.

FDA approved nusinersen (Spinraza, Biogen), the first drug to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

Deaths due to opioid abuse have risen sharply-and show no signs of leveling off. Here’s how data analytics can prevent abuse and diversion.

While the second feed may not change providers’ actions in terms of the strategy they’re implementing for the Comprehensive Care for Joint Replacement program, the findings should change their expectations.

Find out how healthcare executives feel about the industry moving into 2017.

Adding non-opioid postsurgical options to hospital formularies should be a top consideration.

Mental health advocate Patrick J. Kennedy talks to Managed Healthcare Executive about reform, mental health equity, and how payers can help integrate care in mental health.

A Trump administration is expected to have far-reaching impacts on healthcare. Here are nine changes to keep on your radar.

Medicare plans must understand the impact of CMS rule change to be prepared for risk adjustment in 2017. Here are 10 tips to better manage the risk adjustment process.

Study: ACOs can be part of the structure to improve outcomes in children with medical complexity.

Here’s what managed healthcare executives should keep an eye on moving into the new year.

FDA issued two important drug warnings this week: one linking certain diabetes medications to bladder cancer and another about the use of general anesthetic and sedation drugs during pregnancy.

Humana and Oak Street Health share the challenges and opportunities of moving away from the fee-for-service model to value-based care.

As 2016 comes to a close, how do healthcare leaders feel about the state of the industry? Here’s your chance to find out.

The 21st Century Cures Act, a landmark medical research bill, offers healthcare executives a promising future.

Industry leaders share their sources of inspiration.

Pharmaceutical manufacturer relationships and next-gen value based contracts are primed to accelerate value-derivation from your drug spend.

Experts share their ideas on how President-elect Trump could change the single largest source of insurance in the country.

In the aftermath of the presidential election, health policy experts have less to go on than they have after any election in memory.

“Repeal and replace” or “replace and improve” activities on The Hill, though not “business as usual,” won’t necessary slow down data-driven focus areas in healthcare that will continue in 2017.

FDA recently approved bevacizumab (Avastin, Genentech) for patients with platinum-sensitive recurrent epithelial ovarian (psOC), fallopian tube or primary peritoneal cancer.

Results from Managed Healthcare Executive’s annual State of the Industry Survey reveal which issues will hit managed healthcare hardest in 2017.

We have a path to ending the HIV epidemic in the United States, but it requires health plans and healthcare purchasers to take a more active role in getting us there.

The US growth rate for spending on medicines is expected to fall in 2016 and beyond, according to new research.

As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.

President-elect Trump named Tom Price and Seema Verma to lead HHS and CMS, respectively. Here’s what you should know about them.

Inherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.